Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004626-28-FI

Enrollment

Registered

2013-11-20

Start date

2013-12-20

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders

Interventions

Trade Name: REBIF Product Name: beetainterferoni -1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: IU international

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate weather the present multiple sclerosis therapies have an effect on microglial activation;Secondary Objective: To evaluate the effect of the present multiple sclerosis drugs on MRI parameters;Primary end point(s):	—

Secondary

Measure	Time frame
Secondary end point(s): To evaluate the treatment effect of standard therapies using MRI parameters	—

Countries

Finland

Contacts

Public ContactTurku University Hopsital

Turku University Hospital

laura.airas@tyks.fi

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026